10-Q
Quarterly Report
AGENUS INC
AGEN
NASDAQ
CIK: 1098972
File #: 000-29089
Balance Sheet
64 line items · 2 periods
XBRL
| Item | Sep 30, 2025 | Dec 31, 2024 |
|---|---|---|
ASSETS | ||
Cash and cash equivalents | 3,458,000 | 40,437,000 |
Cost | 413,000 | 6,954,000 |
Institutional Money Market Funds - Estimated Fair Value | 413,000 | 6,954,000 |
Institutional Money Market Funds - Cost | 413,000 | 6,954,000 |
Estimated Fair Value | 413,000 | 6,954,000 |
Accounts receivable | 538,000 | 407,000 |
Related party note receivable from MiNK Therapeutics, Inc. | 5,725,000 | — |
Level 3 | 0 | — |
Quoted Prices in Active Markets for Identical Assets (Level 1) | 0 | — |
Level 2 | 5,725,000 | — |
Related Parties | 5,725,000 | 0 |
Prepaid expenses | 885,000 | 2,315,000 |
Assets held for sale | 122,149,000 | 0 |
Other current assets | 1,195,000 | 2,415,000 |
Total current assets | 133,950,000 | 45,574,000 |
MiNK Therapeutics, Inc. | 14,534,000 | — |
Property, plant and equipment, net of accumulated amortization and depreciation of $47,166 and $72,553 at September 30, 2025 and December 31, 2024, respectively | 15,987,000 | 120,087,000 |
Operating lease right-of-use assets | 8,027,000 | 27,308,000 |
Goodwill | 24,092,000 | 24,092,000 |
Acquired intangible assets, net of accumulated amortization of $17,240 and $16,986 at September 30, 2025 and December 31, 2024, respectively | 3,122,000 | 3,376,000 |
Equity method investment in MiNK Therapeutics, Inc. | 30,482,000 | 0 |
MiNK Therapeutics, Inc. | 51,300,000 | — |
Agenus Inc. | 15,000,000 | — |
Related Parties | 15,043,000 | 0 |
Other long-term assets | 3,188,000 | 5,834,000 |
Total assets | 233,891,000 | 226,271,000 |
LIABILITIES AND STOCKHOLDERS' DEFICIT | ||
Current portion, long-term debt | 10,610,000 | 2,698,000 |
Debentures | 146,000 | 146,000 |
Other services | 188,000 | 81,000 |
2015 Subordinated Notes | 10,277,000 | 2,471,000 |
Current portion, liability related to sale of future royalties and milestones | 103,047,000 | 111,978,000 |
Current portion, deferred revenue | 45,000 | 31,000 |
Current portion, operating lease liabilities | 1,113,000 | 2,446,000 |
Accounts payable | 85,289,000 | 61,470,000 |
Accrued liabilities | 31,752,000 | 34,961,000 |
Liabilities held for sale | 54,566,000 | 0 |
Other current liabilities | 710,000 | 7,817,000 |
Total current liabilities | 287,132,000 | 221,401,000 |
MiNK Therapeutics, Inc. | 13,434,000 | — |
Long-term debt, net of current portion | 23,599,000 | 30,473,000 |
2015 Subordinated Notes | — | 10,500,000 |
Promissory Note | 23,598,000 | 19,973,000 |
Liability related to sale of future royalties and milestones, net of current portion | 192,126,000 | 224,389,000 |
Deferred revenue, net of current portion | 1,143,000 | 1,143,000 |
Operating lease liabilities, net of current portion | 10,383,000 | 54,551,000 |
Other long-term liabilities | 376,000 | 738,000 |
STOCKHOLDERS" DEFICIT | ||
Series A-1 convertible preferred stock | 0 | 0 |
Common stock, par value $0.01 per share; 800,000,000 shares authorized; 32,814,429 and 23,634,670 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively | 329,000 | 236,000 |
Additional paid-in capital | 1,899,281,000 | 1,857,662,000 |
Accumulated other comprehensive loss | (1,560,000) | (1,398,000) |
Accumulated deficit | (2,172,187,000) | (2,182,880,000) |
Total stockholders' deficit attributable to Agenus Inc. | (274,137,000) | (326,380,000) |
Non-controlling interest | (6,731,000) | 19,956,000 |
Total stockholders' deficit | (280,868,000) | (306,424,000) |
Non-controlling Interest | (6,731,000) | 19,956,000 |
Series A-1 convertible preferred stock - Preferred Stock | 0 | 0 |
Accumulated Deficit | (2,172,187,000) | (2,182,880,000) |
Common Stock | 329,000 | 236,000 |
Additional Paid-in Capital | 1,899,281,000 | 1,857,662,000 |
Accumulated Other Comprehensive Income (Loss) | (1,560,000) | (1,398,000) |
Total liabilities and stockholders' deficit | 233,891,000 | 226,271,000 |